What's in Brian J Lipworth's pipeline?

Brian J Lipworth has 7 drugs in our index: 7 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Brian J Lipworth's portfolio?

Top competitors by shared drug class: Association Asthma, Bulgaria, Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona, CHU de Quebec-Universite Laval, Eli Lilly and Company, GlaxoSmithKline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/brian-j-lipworth.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Brian J Lipworth — Portfolio Competitive Intelligence Brief

Brian J Lipworth pipeline: 7 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Fluticasone propionate 50 micrograms per actuation	Fluticasone propionate 50 micrograms per actuation	marketed
Placebo to Prazosin	Placebo to Prazosin	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor	Cardiovascular; Urology; Psychiatry (off-label)
oxymetazoline-fluticasone propionate	oxymetazoline-fluticasone propionate	marketed	Nasal decongestant/corticosteroid combination	Alpha-2 adrenergic receptor; glucocorticoid receptor	Otolaryngology/Rhinology
Budesonide/formoterol and tiotropium	Budesonide/formoterol and tiotropium	marketed	Combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor	Respiratory/Pulmonology
Oxymetazoline 0.05% w/v	Oxymetazoline 0.05% w/v	marketed	Alpha-1 adrenergic agonist (nasal decongestant)	Alpha-1 adrenergic receptor	Otolaryngology / Respiratory
placebo to levocetirizine	placebo to levocetirizine	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 receptor	Allergy/Immunology
Seretide 250/placebo via Synchro-Breathe	Seretide 250/placebo via Synchro-Breathe	marketed	Combination inhaled corticosteroid and long-acting beta-2 agonist (ICS/LABA)	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)	Respiratory/Pulmonology

Therapeutic area mix

Respiratory/Pulmonology · 2
Allergy/Immunology · 1
Cardiovascular; Urology; Psychiatry (off-label) · 1
Otolaryngology / Respiratory · 1
Otolaryngology/Rhinology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Association Asthma, Bulgaria · 1 shared drug class
Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona · 1 shared drug class
CHU de Quebec-Universite Laval · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Goldman, Butterwick, Fitzpatrick and Groff · 1 shared drug class
HK inno.N Corporation · 1 shared drug class
AAADRS Clinical Research Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Brian J Lipworth:

Cite this brief

Drug Landscape (2026). Brian J Lipworth — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/brian-j-lipworth. Accessed 2026-05-16.